Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.
暂无分享,去创建一个
A. Ardizzoni | L. Boni | G. Ferrara | F. Grossi | C. Pera | P. Ceppa | J. Serrano | M. Loprevite | L. Boni | G. Ratto | R. Costa | M. Chiaramondia | A. Ardizzoni
[1] J. Jett,et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] T. Mitsudomi,et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] M. Volm,et al. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival , 2000, British Journal of Cancer.
[4] T. Horie,et al. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. , 2000, European journal of cancer.
[5] J. Muscat,et al. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. , 1999, Carcinogenesis.
[6] E. Brambilla,et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF‐R1‐Flt1 and VEGF‐R2‐Flk1/KDR) in non‐small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival , 1999, The Journal of pathology.
[7] M. Volm,et al. Biological characterization of subgroups of squamous cell lung carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] M. Higashiyama,et al. A novel molecular staging protocol for non-small cell lung cancer , 1999, Oncogene.
[9] H. Dosaka-akita,et al. Bcl-2 Expression in Non-Small Cell Lung Cancers: Higher Frequency of Expression in Squamous Cell Carcinomas with Earlier pT Status , 1999, Oncology.
[10] M. Rooney,et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Brousset,et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer , 1999, British Journal of Cancer.
[12] W. Richards,et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] H. Ishida,et al. The prognostic significance of p53 and bcl‐2 expression in lung adenocarcinoma and its correlation with ki‐67 growth fraction , 1997, Cancer.
[14] M. Buyse,et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Aktaş,et al. Apoptosis bcl-2 and p53 expression and their relation to tumour stage in non-small cell lung carcinomas (NSCLC). , 1997, Cancer letters.
[16] C. Angeletti,et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. , 1997, Journal of the National Cancer Institute.
[17] S. Graziano. Non-small cell lung cancer: clinical value of new biological predictors , 1997 .
[18] J. Roh,et al. Correlation between K‐ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma , 1997, Cancer.
[19] S. Fox,et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.
[20] A. Ariza,et al. Molecular staging of non-small cell lung cancer according to K-ras genotypes. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] J. Siegfried,et al. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] Y. Soini,et al. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. , 1995, Cancer research.
[23] M. Wick,et al. Expression of bcl-2 protein in stage T1NOMO non-small cell lung carcinoma , 1995 .
[24] K. Yamamoto,et al. Studies on clinicopathological features of lung cancer patients with K-ras/p53 gene alterations: comparison between younger and older groups. , 1995, Oncology.
[25] C. Angeletti,et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.
[26] S. Rodenhuis,et al. Comparative analysis of p53 gene mutations and protein accumulation in human non‐small‐cell lung cancer , 1995, International journal of cancer.
[27] J. Izbicki,et al. p53 in non-small-cell lung cancer. , 1994, Journal of the National Cancer Institute.
[28] S. Steinberg,et al. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. , 1994, Cancer research.
[29] U. Veronesi,et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. , 1994, Journal of the National Cancer Institute.
[30] A. Harris,et al. bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.
[31] A. Marchetti,et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. , 1993, Cancer research.
[32] S. Goodman,et al. Overexpression of the p53 Tumor Suppressor Gene Product in Primary Lung Adenocarcinomas Is Associated with Cigarette Smoking , 1993, The American journal of surgical pathology.
[33] C. Angeletti,et al. The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node‐negative non‐small cell lung cancer , 1992, Cancer.
[34] K. Sugimachi,et al. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. , 1992, Cancer research.
[35] S. Steinberg,et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.
[36] S. Rodenhuis,et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.
[37] W. McGuire,et al. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors , 1990, Cancer.
[38] S. Rodenhuis,et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.
[39] C. Mountain. The new International Staging System for Lung Cancer. , 1986, The Surgical clinics of North America.
[40] M. Gail,et al. Prognostic factors in patients with resected stage I non‐small cell lung cancer. A report from the Lung Cancer Study Group , 1984, Cancer.
[41] G W Moore,et al. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung , 1984, The American journal of surgical pathology.
[42] D. Crowther,et al. Cancer—Principles and Practice of Oncology. V , 1982, British Journal of Cancer.
[43] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[44] Ahmedin Jemal,et al. Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.
[45] J. Jassem,et al. Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer. , 2002, Lung cancer.
[46] T. Oyama,et al. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma. , 2000, Anticancer Research.
[47] K. Sugimachi,et al. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. , 1997, British Journal of Cancer.
[48] D. Jacobson,et al. Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] D. Harpole,et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. , 1995, Cancer research.
[50] Rupert G. Miller,et al. Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.
[51] A. Liebow. Tumors of the lower respiratory tract , 1952 .